SCHEMBL756791

SCHEMBL756791

[CH2]S(=O)(=O)c1ccc(NC(C)=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.67
CA2 P00918 4/20 0.67
CA12 O43570 3/20 0.67
CA9 Q16790 3/20 0.67
MMP1 P03956 1/20 0.65
MMP2 P08253 1/20 0.65
MMP9 P14780 1/20 0.65
MMP8 P22894 1/20 0.65
MMP13 P45452 1/20 0.65
PKM P14618 2/20 0.62
POLB P06746 3/20 0.61
CYP2C19 P33261 1/20 0.61
KMT2A Q03164 4/20 0.59
MAPT P10636 3/20 0.59
ALDH1A1 P00352 2/20 0.59
HTT P42858 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
KDM4E B2RXH2 1/20 0.57
F2 P00734 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acedapsone SCHEMBL152710 0.83 PKM (0.85) CA1CA2CA12CA9MMP1
Acedapsone SCHEMBL22518385 0.82 PKM (0.82) CA1CA2CA12CA9MMP1
SCHEMBL1102016 0.82 CA1 (0.69) CA1CA2CA12CA9MMP1
SCHEMBL8009645 0.82 CA1 (0.69) CA1CA2CA12CA9MMP1
SCHEMBL756792 0.82 CA1 (0.69) CA1CA2CA12CA9MMP1
Acedapsone SCHEMBL28716352 0.82 PKM (0.82) CA1CA2CA12CA9MMP1
SCHEMBL2372596 0.81 CA1 (0.71) CA1CA2CA12CA9MMP1
SCHEMBL754757 0.81 POLB (0.65) CA1CA2CA12CA9MMP1
SCHEMBL11847210 0.80 CA1 (0.67) CA1CA2CA12CA9MMP1
SCHEMBL12916667 0.80 CA1 (0.67) CA1CA2CA12CA9MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867211-B1 METHOD FOR PREPARATION OF MEDETOMIDINE WITH CHLOROACETONE LONZA AG (CH) 2015-12-30 EP claimed
EP-2847173-B1 METHOD FOR PREPARATION OF MEDETOMIDINE LONZA AG (CH) 2015-12-30 EP claimed
EP-1805147-B1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 EP claimed
US-8586616-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA, NV (BE) 2013-11-19 US claimed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US claimed
EP-1805147-A1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 EP claimed
US-20060116412-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US claimed
WO-2006039243-A1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-04-13 WO claimed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US claimed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP claimed
EP-1812406-B1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2018-09-12 EP disclosed
EP-1805147-B1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 EP disclosed
US-8586616-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA, NV (BE) 2013-11-19 US disclosed
EP-1847534-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2012-03-21 EP disclosed
EP-1847534-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-06-22 EP disclosed
US-20060111402-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-25 US disclosed
WO-2006039243-A1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-04-13 WO disclosed
WO-2006039215-A2 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-04-13 WO disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 CA1 4761/4885CA2 4175/4885CA12 4720/4885
US-20060111402-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) AR, NR5A1, ESRRA CA1 4851/4885CA2 4411/4885CA12 4708/4885
US-20060116412-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) AR, NR5A1, ESRRA CA1 4851/4885CA2 4411/4885CA12 4708/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 CA1 4761/4885CA2 4175/4885CA12 4720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.